A 60-year-old male presented to clinic with HIV and a history of intravenous drug use more than a decade ago. While incarcerated more than 10 years ago, he was diagnosed with HIV (via two ELISA tests, followed by a confirmatory western blot) but never followed up for care. Three years prior to presentation, he was incarcerated again, during which time routine testing reconfirmed his HIV, but he was told that he did not need treatment because his CD4+ count was above the threshold (>250 cells/uL) for consideration of ART. Upon discharge from the penitentiary, the patient planned to follow up in the community but had not done so until 2 years ago. At that visit two years prior to current presentation, he reported feeling "very good" and experienced no symptoms related to his HIV. Laboratory testing showed a CD4+ count of 6900/uL, HCV viral load <43 copies/mL, and HIV viral load <48 copies/mL ( Table 1) . The patient was then lost to follow up. At this presentation, the patient reported being in good health over the past two years. He stated he did not have any symptoms related to his HIV infection and did not return to clinic because he felt healthy. 2 Certain individuals, termed "elite controllers" or natural viral suppressors (NVS), maintain normal CD4+ counts (500-1200 cells/mL), rarely develop clinical disease, and are less likely to transmit HIV. One study examining 40 elite controllers found a very low rate of progression to AIDS, with only one subject progressing 15 years after the initial diagnosis. 3 Elite controllers represent a very small percentage of the HIV population with studies estimating an incidence of 1.1% and a prevalence ranging from 0.6% -1.5%. 3, 4 The International HIV Controllers Study evaluated 974 NVS and identified >300 genome wide single-nucleotide polymorphisms (SNP) within major histocompatibility complex (MHC) that dictate human leukocyte antigen (HLA) viral peptide interaction as the major genetic factor modulating durable control of HIV infection. 5 Once inside an antigen presenting cell (APC), HIV associated proteins are degraded into small peptides, typically nine amino acids in length, and expressed on the cell surface HLA class I molecule. This virus processing and protein presentation are genetically determined and the major determinant of host control of HIV. Specifically, the molecular structure of HLA is associated with disease progression, with one of the most significant polymorphisms resulting in position 97 in the floor of the peptide-binding groove of HLA-B. 5 However, when looking at large, clinically well-defined cohorts, researchers have also pinpointed other binding sites within HLA-B accounting for the varying progression of HIV to AIDS. For example, amino acid substitutions at positions 114 and 116 of the HLA-B heavy chain alter the ability of the protein complex to bind tyrosine at the carboxy-terminal anchor. This varying ability to bind tyrosine may be the critical distinction between HLA-B genotypes and ultimately influence the presentation of specific HIV epitopes to cytotoxic T lymphocytes. Because of the overlying genetic effect on disease progression, genetic testing of HIV infected patients, specifically aimed at the HLA-B alleles, could be developed in order provide more or less aggressive therapeutic regimens for patients. Furthermore, researchers believe further study aimed at characterizing cytotoxic-T-lymphocyte activity in HIV infected patients, especially in elite-controllers, may highlight mechanisms involved in HIV susceptibility. 6 This patient has maintained normal laboratory values during a two-year period for HIV, despite having never received ART. He also managed to autonomously clear Hepatitis C. NVS patients clear HCV infection at an elevated rate (23.3%) compared to HCV-monoinfected (9.1%) and HIV/HCV-coinfected individuals (6.5%). 7 Therefore, the patient qualifies as an "elite controller" of the HIV infection. Of note, the patient maintained an elevated CD4+/CD8+ ratio without need for ART for the past two years. With a greater prognostic value than either the absolute or percentage CD4+ count, the CD4+/CD8+ ratio has been noted to be protective over various types of non-AIDS associated morbidity and mortality, including ischemic heart disease, stroke, and non-AIDS malignancies. [8] [9] [10] [11] Furthermore, the CD4+/CD8+ ratio has been shown to be better than CD4+ or CD8+ alone to determine risk of non-AIDS events including hypertension, diabetes, cardiovascular disease, liver failure, kidney failure, peripheral neuropathy, and cognitive decline. 8, 11 According to the US Department of Defense HIV Natural History study, researchers concluded that elite controllers not only had significantly fewer AIDS defining events but also had a longer time to death and AIDS diagnosis compared to HIV noncontrollers. 12 As seen with this patient, the elevated CD4+/CD8+ ratio has proven to be a protective measure of overall health status. Moving forward, researchers hope to identify characteristics of patients, including lifestyle and cellular markers that predispose patients to a healthy CD4+/CD8+ ratio. Learning from the unique characteristics of elite controllers, especially their innate and adaptive immunity, opens the door to develop treatment modalities such as T cell vaccines aimed at reducing HIV replication, progression, and transmission. However, to achieve this understanding, immune protection in vivo as in elite-controllers must be thoroughly determined.
13 From this point researchers plan to identify the unique social, behavioral, and biochemical characteristics of "elite controllers" in order to understand the mechanisms by which HIV can be autonomously controlled and apply these factors to the HIV population at large.
• Elite controllers of HIV have the unique ability to maintain a healthy CD4+ count and suppressed viral load without the use of antiretroviral therapy (ART).
• Elite controllers of HIV may clear HCV infection at an elevated rate.
• The elevated CD4+/CD8+ ratio in this HIV patient may be a protective measure over various types of non-AIDS associated morbidity and mortality, including hypertension, diabetes mellitus, cardiovascular disease, pulmonary hypertension, cancer, osteopenia, osteoporosis, liver and kidney failure, peripheral neuropathy, frailty, and cognitive decline.
